All In Biotech

Drug Trial Radar · NCT02586909

12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Apr 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,099

Actual

Start

Apr 26, 2016

Primary completion

Mar 12, 2018

Study completion Mar 12, 2018

Sponsor

Lead sponsor
Axovant Sciences Ltd.Industry
Sponsor type
Industry
First posted
Oct 27, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 50 years, up to 86 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001 (double-blind study).

Conditions

  • Alzheimer's Disease

Interventions

  • RVT-101 35 mg tabletsDrug

    once daily, oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Adverse Events (AEs) and or Reported Changes in Physical Examinations, Vital Signs Measurements, Electrocardiograms (ECGs), Routine Laboratory AssessmentsTime frame: Baseline to 12 months or Early Termination

Locations

169 sites in 19 countries. Site status is shown where the registry gives one.

  • US112

    Phoenix, Arizona

  • US220

    Tucson, Arizona

  • US096

    Rancho Mirage, California

  • US195

    Santa Ana, California

  • US016

    Simi Valley, California

  • US106

    Temecula, California

  • US179

    Hamden, Connecticut

  • US171

    Norwich, Connecticut

  • US088

    Atlantis, Florida

  • US007

    Brooksville, Florida

  • US002

    Hallandale, Florida

  • US140

    Hialeah, Florida

  • US216

    Miami, Florida

  • US110

    Miami, Florida

  • US172

    North Palm Beach, Florida

  • US003

    Orlando, Florida

  • US256

    Pensacola, Florida

  • US037

    Tampa, Florida

  • US042

    Tampa, Florida

  • US004

    The Villages, Florida

  • US048

    Atlanta, Georgia

  • US046

    Atlanta, Georgia

  • US217

    Columbus, Georgia

  • US111

    Baton Rouge, Louisiana

  • US095

    Shreveport, Louisiana

  • US116

    Newton, Massachusetts

  • US174

    Quincy, Massachusetts

  • US144

    Hattiesburg, Mississippi

  • US094

    Las Vegas, Nevada

  • US135

    Berlin, New Jersey

  • US197

    Lawrenceville, New Jersey

  • US215

    Mount Arlington, New Jersey

  • US057

    Paterson, New Jersey

  • US209

    Toms River, New Jersey

  • US036

    West Long Branch, New Jersey

  • US001

    Albany, New York

  • US049

    Brooklyn, New York

  • US097

    New Hyde Park, New York

  • US044

    New York, New York

  • US150

    Chapel Hill, North Carolina

Showing 40 of 169 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.